Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation
about
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMSRisk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation.Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma.Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy.Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
P2860
Q33420631-2F3A5949-A5ED-42E8-A1C9-568E704E9DE5Q34036696-7968A13E-1207-4F0A-B2F4-AA003A058CE5Q35059058-CB57035F-308A-4C2C-A4DB-CC350A3D04CAQ36036173-001625B6-5665-4D06-8ECB-8F62ED3443A6Q37316657-A308DDAD-8CE3-4440-B96D-A3ADA02DE606Q37675281-CA12E623-5306-418A-89C0-2206DF56AC6DQ38552083-109AB16B-A0EC-4501-B29C-99C4535B0964Q38684561-E4DC6066-20CE-4D7F-A5B4-FF56BF5820B0Q39005626-E1E9AA58-2304-41AB-89D3-28275953827CQ40432531-074D075D-DC19-4375-A40D-100EA34DC1F8Q43246067-276C4FD5-9DFA-4408-AD4C-06C00D51D843Q48606065-38427580-F7E5-4350-8EB2-DA101BEDD587Q48786872-C953C460-838F-4A36-84DC-4C7A5692C54DQ52881184-AE91D8B1-8175-4A3F-AFEC-7870A09EB0C4
P2860
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation
description
im August 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 August 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2006
@uk
name
Morbidity and transplant-relat ...... gous stem-cell transplantation
@en
Morbidity and transplant-relat ...... gous stem-cell transplantation
@nl
type
label
Morbidity and transplant-relat ...... gous stem-cell transplantation
@en
Morbidity and transplant-relat ...... gous stem-cell transplantation
@nl
prefLabel
Morbidity and transplant-relat ...... gous stem-cell transplantation
@en
Morbidity and transplant-relat ...... gous stem-cell transplantation
@nl
P2093
P2860
P1433
P1476
Morbidity and transplant-relat ...... gous stem-cell transplantation
@en
P2093
Carmen Jiménez
Guillermo F Sanz
Ignacio Lorenzo
Isidro Jarque
Jaime Sanz
Jesús A Martínez
Luca Cupelli
María J Remigia
Miguel A Sanz
Noemí Puig
P2860
P304
P356
10.1080/10428190500527769
P577
2006-08-01T00:00:00Z